Research programme - cancer therapeutics - Suvica

Drug Profile

Research programme - cancer therapeutics - Suvica

Alternative Names: SVC 112

Latest Information Update: 28 Sep 2016

Price : $50

At a glance

  • Originator University of Colorado at Boulder
  • Developer Suvica
  • Class Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 Sep 2016 Research programme - cancer therapeutics - Suvica is available for licensing as of 28 Sep 2016.
  • 28 Sep 2016 Suvica files for patent protection for SVC 112 (Suvica pipeline, September 2016)
  • 15 Oct 2015 Suvica receives SBIR grant from National Institutes of Health for development of therapies in Head and neck cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top